Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents - Wikidata - awgldk - TriplyDB

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

http://www.wikidata.org/entity/Q36645808

about

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory Diseases Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade Role of histone deacetylases in pancreas: Implications for pathogenesis and therapy Therapeutic efficacy of valproic acid in a combined monocrotaline and chronic hypoxia rat model of severe pulmonary hypertension 2-Benzazolyl-4-Piperazin-1-Ylsulfonylbenzenecarbohydroxamic Acids as Novel Selective Histone Deacetylase-6 Inhibitors with Antiproliferative Activity Effects of valproic acid and pioglitazone on cell cycle progression and proliferation of T-cell acute lymphoblastic leukemia Jurkat cells Evaluation of the Therapeutic Potential of the Novel Isotype Specific HDAC Inhibitor 4SC-202 in Urothelial Carcinoma Cell Lines.Combination therapy with the histone deacetylase inhibitor LBH589 and radiation is an effective regimen for prostate cancer cells.Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndrome Antitumor effects in hepatocarcinoma of isoform-selective inhibition of HDAC2.HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: where do we stand?Suberoylanilide hydroxamic acid (SAHA)-induced dynamics of a human histone deacetylase protein interaction network Identification of small molecule modulators of gene transcription with anticancer activity.The potential of panobinostat as a treatment option in patients with relapsed and refractory multiple myeloma.Epigenomic regulation of host-microbiota interactions.Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer.Epigenomics and the microbiota.Discovery of Novel Multiacting Topoisomerase I/II and Histone Deacetylase Inhibitors Comparative pharmacokinetic properties and antitumor activity of the marine HDACi Largazole and Largazole peptide isostere Tackling the Cytotoxic Effect of a Marine Polycyclic Quinone-Type Metabolite: Halenaquinone Induces Molt 4 Cells Apoptosis via Oxidative Stress Combined with the Inhibition of HDAC and Topoisomerase Activities.The correlation between telomerase activity and Bax/Bcl-2 ratio in valproic acid-treated MCF-7 breast cancer cell line Epigenetic Library Screen Identifies Abexinostat as Novel Regulator of Adipocytic and Osteoblastic Differentiation of Human Skeletal (Mesenchymal) Stem Cells Selective inhibition of histone deacetylase 2 induces p53-dependent survivin downregulation through MDM2 proteasomal degradation Valproic Acid Limits Pancreatic Recovery after Pancreatitis by Inhibiting Histone Deacetylases and Preventing Acinar Redifferentiation Programs Induction of MAPK- and ROS-dependent autophagy and apoptosis in gastric carcinoma by combination of romidepsin and bortezomib Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies Reverse the Resistance to PARP Inhibitors.TACC3 overexpression in cholangiocarcinoma correlates with poor prognosis and is a potential anti-cancer molecular drug target for HDAC inhibitors A histone deacetylase inhibitor improves hypothyroidism caused by a TRα1 mutant.Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression.Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.Epigenetic pathway targets for the treatment of disease: accelerating progress in the development of pharmacological tools: IUPHAR Review 11.The role of dietary histone deacetylases (HDACs) inhibitors in health and disease.Gold-chrysophanol nanoparticles suppress human prostate cancer progression through inactivating AKT expression and inducing apoptosis and ROS generation in vitro and in vivo.Induction of Activating Transcription Factor 3 Is Associated with Cisplatin Responsiveness in Non-Small Cell Lung Carcinoma Cells.Cell-based laboratory evaluation of coagulation activation by antineoplastic drugs for the treatment of lymphoid tumors.Chemosensitivity enhancement toward arsenic trioxide by inhibition of histone deacetylase in NB4 cell line.Combination of panobinostat with ponatinib synergistically overcomes imatinib-resistant CML cells Histone deacetylases inhibitors effects on Cryptococcus neoformans major virulence phenotypes

P2860

Q26739120-FDCFB79C-1C72-4943-A037-EC8BE1B2BA40 Q26769977-C4674439-FB1E-4561-AC74-77A0E5424B12 Q26774080-F078BA67-7DE1-4565-A370-2AEB5E852B2A Q27316522-1AF6D19E-9735-4CB2-9925-0B21D421A9EB Q28551721-747018B8-CD2A-44AB-946F-BD214B8136D5 Q28831371-F781FF58-8968-47E3-8C87-3CF78229C609 Q30489412-9377649D-53E6-48AD-AC3A-ADA3B5860132 Q31133958-BBAB5167-9358-4DC2-8053-6D4E1A803411 Q33889309-AF5D10FE-9A8A-4DBF-84F1-B3E5284390A3 Q34135528-DE7FEC5F-F24B-4273-8390-63BC7522183F Q34410902-03DC4E85-585A-4281-8E9B-709CCF26B245 Q34468386-5A2DFAFB-07FA-4741-8F43-9A0ED5ED7C34 Q34576203-A17CDD8D-CE51-4522-AFE0-18B333E1642E Q34602263-AFA6A520-0CBE-43D0-9CE3-361426D2D16B Q34625951-F9A4FAE7-D850-4907-A36E-74B232303E69 Q35000789-17924604-0FB3-4BEA-9297-AE82B9A3BF3E Q35027853-BBB2F677-98AA-4B6E-A253-6C78C4345B5A Q35178901-F2D31ACF-D3BD-4304-8927-6B5BD5D3D4E6 Q35202369-FA41C612-CD32-4337-AC15-5E45ED633BE2 Q35640652-4BA017F4-8372-4D60-B2A6-C6635319F9B7 Q36017178-8218AF03-718E-4917-97F2-3387D4B7B6CB Q36021958-13707841-EC95-45BA-9CC5-F6B60D1490A3 Q36413516-7002DFB3-E604-4F59-AC40-F2F583BBA112 Q36509087-74E183F7-AA63-4384-AD24-2234981F9685 Q36782473-023FBC97-6525-4B8C-A929-CAF283B55A79 Q37226511-A7F69B86-BF28-4739-805D-455B0265E3CD Q37675896-8C77B574-42E7-48C1-90B7-55897E678963 Q37688959-7BD21B01-18E0-4D14-B787-70C65461DEAA Q37708375-C3B746BA-F076-4BE1-9333-50AF50A194A8 Q37716414-6CD80690-412D-41B3-B26D-6C29E84EDD9C Q38204487-49C48FE8-EDB9-42A1-B623-FC284CE95F9E Q38204866-6BB2332A-0526-43C0-AD81-A4406F31CAAD Q38233723-7A763E24-E9C3-47B1-9A47-14099C8D06D9 Q38260795-C42E6E4E-F545-4B14-84CB-812E5175236E Q38604581-B0051D1A-0ED4-4B28-862F-E61D0D45EAD5 Q38744268-F7907EC7-09D3-4036-8D9B-304410AA4BC0 Q38752911-F8D60B9D-9103-4346-81BA-D9093C4BC080 Q38770298-95998881-297C-4F7D-9468-D07818825D42 Q38771802-8CEFD8CF-D8C6-4C24-8CAB-F83E508622FC Q38919839-56423A43-58DE-44A5-B5FA-6962859ECD31

P2860

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

http://www.wikidata.org/entity/Q36645808

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

@ast

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

@en

type

label

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

@ast

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

@en

prefLabel

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

@ast

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

@en

P1433

Q36645808-E73A6186-2F3B-4B58-86A2-A10C94A7737B

P1476

Q36645808-AAFE4E0B-9EFE-4220-8B8E-41D289AEE90C

P2093

Q36645808-3A8662F3-40DB-4972-B92A-39D2CC0C2189

Q36645808-B5B75CD0-089A-41F4-8FC2-A66DDC862FCD

Q36645808-B7784B12-4DFA-433D-8237-518BD8B28CBD

Q36645808-C5F3B9C0-3DBE-47A2-BACD-08093F6A5AAB

P2860

Q36645808-045E2710-8291-4833-938A-E0DCB47B9166

Q36645808-04838711-CEBC-4239-B6B4-0177B62F9DD6

Q36645808-05E0FB5A-4BE4-4F49-BC5F-EB1336B4E903

Q36645808-05E73E74-5965-4C8D-B0C8-9463D1A6BEE0

Q36645808-06FA1354-5657-4BF3-B1F9-35F7D2171F99

Q36645808-07676E86-7FAD-4FF1-9442-86D0E64DD516

Q36645808-09ADF90D-78CD-4C1A-AB91-3DC369F0BAF0

Q36645808-0BA5D6A1-81D7-4C97-984A-94D29C8CA625

Q36645808-0C22F903-9E17-400D-8AE6-C7CE98D63C37

Q36645808-0C982141-40BE-429F-9379-CCF6AB8BBE8E

P304

Q36645808-545E0627-9652-4F29-9998-E3861C47DDB1

P31

Q36645808-06A253F3-6ED4-4D2D-9624-79D26575411A

P356

Q36645808-78675D0E-EB7A-4F82-9E6C-C1E6993E1566

P478

Q36645808-1D3EA724-3BB1-4A4E-8D5E-BD094F73C002

P577

Q36645808-04989D1C-4233-4363-A7FB-F2D1EBADC14D

P698

Q36645808-FBB0601B-84AC-4449-961F-63B4A2A01BFF

P932

Q36645808-CEB98825-6849-4951-9E0E-B33F2C9C8C5D

P356

P1433

Biologics: Targets and Therapy

P1476

Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents

@en

P2093

Alison Hiong

http://www.w3.org/2001/XMLSchema#string

Katherine Ververis

http://www.w3.org/2001/XMLSchema#string

Paul V Licciardi

http://www.w3.org/2001/XMLSchema#string

Tom C Karagiannis

http://www.w3.org/2001/XMLSchema#string

P2860

Translating the Histone Code

HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor

Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha

HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation

Histone deacetylases (HDACs): characterization of the classical HDAC family

MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation

Regulation of transcription factor YY1 by acetylation and deacetylation

Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy

The many roles of histone deacetylases in development and physiology: implications for disease and therapy

The role of human bromodomains in chromatin biology and gene transcription

P304

47-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/BTT.S29965

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2013-02-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23459471

http://www.w3.org/2001/XMLSchema#string

P932

3584656

http://www.w3.org/2001/XMLSchema#string